BNP Paribas Financial Markets’s Avidity Biosciences RNAM Stock Holding History

BNP Paribas Financial Markets’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-610,547	Closed	-$44M	–	6071
2025 Q4	$44M	Buy	610,547 +583,256	+2,137%	+$37.7M	0.02%	752
2025 Q3	$1.19M	Buy	27,291 +10,396	+62%	+$420K	﹤0.01%	3008
2025 Q2	$480K	Buy	16,895 +3,870	+30%	+$115K	﹤0.01%	3346
2025 Q1	$384K	Sell	13,025 -8,583	-40%	-$267K	﹤0.01%	3331
2024 Q4	$628K	Buy	+21,608	New	+$903K	﹤0.01%	3133
2022 Q4	–	Sell	-43,523	Closed	-$711K	–	4502
2022 Q3	$711K	Buy	+43,523	New	+$833K	﹤0.01%	2730

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

BNP Paribas Financial Markets's RNAM Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 610,547 shares — an estimated $44M sold.

BNP Paribas Financial Markets first reported a position in RNAM in Q3 2022 and held it in 6 quarters. The position peaked at $44M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

BNP Paribas Financial Markets reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
BNP Paribas Financial Markets sold 610,547 Avidity Biosciences shares in Q1 2026, an estimated $44M.
BNP Paribas Financial Markets first reported a position in Avidity Biosciences in Q3 2022 and held it in 6 quarters.
BNP Paribas Financial Markets's Avidity Biosciences position peaked at $44M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.